Literature DB >> 7649717

Neuropsychiatric sequelae of stroke and traumatic brain injury: the role of psychostimulants.

M F Kraus1.   

Abstract

OBJECTIVE: The primary purpose of this article is to review certain neuropsychiatric sequelae of stroke and traumatic brain injury (TBI), and the role of the psychostimulants methylphenidate (MPD) and dextroamphetamine (DAMP) in their treatment.
METHOD: A general review of the topic is presented. Controlled and uncontrolled studies involving the use of the psychostimulants are discussed. These consist of 11 studies listed with Medline 2000 that deal specifically with stroke or head injury, with the oldest study reviewed dating back to 1984. Studies concerning the use of psychostimulants in the medically or neurologically ill are reviewed to the extent that they are pertinent.
RESULTS: The current literature consists primarily of uncontrolled case studies. However, these are reviewed and found to suggest a role for the use of the psychostimulants, which is discussed.
CONCLUSIONS: In general, these drugs appear to be a reasonable treatment choice for certain types of mood, behavior, and cognitive symptoms following brain injury. However, it is noted that larger scale controlled studies are needed to adequately assess the clinical usefulness of these drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649717     DOI: 10.2190/BXRM-3M58-WBC5-A7EL

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  2 in total

1.  Strategy Training During Inpatient Rehabilitation May Prevent Apathy Symptoms After Acute Stroke.

Authors:  Elizabeth R Skidmore; Ellen M Whyte; Meryl A Butters; Lauren Terhorst; Charles F Reynolds
Journal:  PM R       Date:  2015-01-13       Impact factor: 2.298

2.  Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial.

Authors:  Martin P Paulus; Rayus Kuplicki; Teresa A Victor; Hung-Wen Yeh; Sahib S Khalsa
Journal:  BMC Psychiatry       Date:  2021-11-19       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.